Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | YL211 |
Synonyms | |
Therapy Description |
YL211 is an antibody-drug conjugate (ADC) comprising an antibody targeting MET linked to a topoisomerase 1 inhibitor, which potentially induces cell cycle arrest and apoptosis and inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 2615). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
YL211 | YL-211|YL 211 | MET Antibody 29 | YL211 is an antibody-drug conjugate (ADC) comprising an antibody targeting MET linked to a topoisomerase 1 inhibitor, which potentially induces cell cycle arrest and apoptosis and inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 2615). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06384352 | Phase I | YL211 | A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors | Recruiting | USA | 0 |